Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Dermacyd PH_DETINLYN (Lactic Acid)
Dermacyd PH_DETINLYN · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Dermacyd PH\_DETINLYN (Lactic Acid) |
| Name | Type | Description |
|---|---|---|
| Dermacyd PH_DETINLYN (Lactic Acid) | DRUG | - |
Inclusion criteria: * Phototype Skin II and III; * Integral skin test in the region; * Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion; Exclusion criteria: * Lactation or gestatio...
Dermacyd PH_DETINLYN is a small molecule product developed by Sanofi, known in full as Dermacyd PH_DETINLYN (Lactic Acid). It has been studied in Phase 3 clinical trials in the hygiene area, specifically in Brazil, in studies enrolling healthy adult female volunteers aged 18 years and older.
Dermacyd PH_DETINLYN is developed by Sanofi, which trades under the ticker SNY. Sanofi sponsored the Phase 3 clinical program for the product, including the compatibility and photo evaluation studies conducted in Brazil.
Dermacyd PH_DETINLYN has been studied in Phase 3 clinical trials. Three Phase 3 studies have been completed, and none are currently active. The program enrolled a total of 132 participants across those completed trials.
Dermacyd PH_DETINLYN has been evaluated in three completed Phase 3 trials: NCT00786097, a Tangerine Mix compatibility study enrolling 53 participants; NCT00785655, a Sweet Flower compatibility study enrolling 53 participants; and NCT00785590, a Sweet Flower photo evaluation study enrolling 26 participants. All were conducted in Brazil.
Dermacyd PH_DETINLYN is also known as Dermacyd PH_DETINLYN (Lactic Acid), reflecting lactic acid as the named component. Searches for either name refer to the same Sanofi product studied in the Phase 3 hygiene trials.
Dermacyd PH_DETINLYN has been studied in the hygiene therapeutic area. Its Phase 3 trials were conducted in healthy adult female volunteers aged 18 years and older in Brazil, evaluating compatibility and photo evaluation endpoints rather than a disclosed disease indication.